Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Autorschaft

  • Stephan Hüttel
  • Giambattista Testolin
  • Jennifer Herrmann
  • Therese Planke
  • Franziska Gille
  • Maria Moreno
  • Marc Stadler
  • Mark Brönstrup
  • Andreas Kirschning
  • Rolf Müller

Organisationseinheiten

Externe Organisationen

  • Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)
  • Deutsches Zentrum für Infektionsforschung (DZIF)
Forschungs-netzwerk anzeigen

Details

Titel in ÜbersetzungEntdeckung und Totalsynthese von natürlichen Cystobactamid-Derivaten mit herausragender Aktivität gegen Gram-negative Pathogene
OriginalspracheEnglisch
Seiten (von - bis)12760-12764
Seitenumfang5
FachzeitschriftAngewandte Chemie
Jahrgang56
Ausgabenummer41
PublikationsstatusVeröffentlicht - 20 Juli 2017

Abstract

Antibiotic discovery and development is challenging as chemical scaffolds of synthetic origin often lack the required pharmaceutical properties, and the discovery of novel ones from natural sources is tedious. Herein, we report the discovery of new cystobactamids with a significantly improved antibacterial profile in a detailed screening of myxobacterial producer strains. Some of these new derivatives display antibacterial activities in the low-μg mL−1 range against Gram-negative pathogens, including clinical isolates of Klebsiella oxytoca, Pseudomonas aeruginosa, and fluoroquinolone-resistant Enterobacteriaceae, which were not observed for previously reported cystobactamids. Our findings provide structure–activity relationships and show how pathogen resistance can be overcome by natural scaffold diversity. The most promising derivative 861-2 was prepared by total synthesis, enabling further chemical optimization of this privileged scaffold.

ASJC Scopus Sachgebiete

Zitieren

Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens. / Hüttel, Stephan; Testolin, Giambattista; Herrmann, Jennifer et al.
in: Angewandte Chemie , Jahrgang 56, Nr. 41, 20.07.2017, S. 12760-12764.

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Hüttel, S, Testolin, G, Herrmann, J, Planke, T, Gille, F, Moreno, M, Stadler, M, Brönstrup, M, Kirschning, A & Müller, R 2017, 'Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens', Angewandte Chemie , Jg. 56, Nr. 41, S. 12760-12764. https://doi.org/10.1002/anie.201705913, https://doi.org/10.1002/ange.201705913
Hüttel, S., Testolin, G., Herrmann, J., Planke, T., Gille, F., Moreno, M., Stadler, M., Brönstrup, M., Kirschning, A., & Müller, R. (2017). Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens. Angewandte Chemie , 56(41), 12760-12764. https://doi.org/10.1002/anie.201705913, https://doi.org/10.1002/ange.201705913
Hüttel S, Testolin G, Herrmann J, Planke T, Gille F, Moreno M et al. Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens. Angewandte Chemie . 2017 Jul 20;56(41):12760-12764. doi: 10.1002/anie.201705913, 10.1002/ange.201705913
Hüttel, Stephan ; Testolin, Giambattista ; Herrmann, Jennifer et al. / Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens. in: Angewandte Chemie . 2017 ; Jahrgang 56, Nr. 41. S. 12760-12764.
Download
@article{cbd43ce32a6e4458951490a451a163b1,
title = "Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens",
abstract = "Antibiotic discovery and development is challenging as chemical scaffolds of synthetic origin often lack the required pharmaceutical properties, and the discovery of novel ones from natural sources is tedious. Herein, we report the discovery of new cystobactamids with a significantly improved antibacterial profile in a detailed screening of myxobacterial producer strains. Some of these new derivatives display antibacterial activities in the low-μg mL−1 range against Gram-negative pathogens, including clinical isolates of Klebsiella oxytoca, Pseudomonas aeruginosa, and fluoroquinolone-resistant Enterobacteriaceae, which were not observed for previously reported cystobactamids. Our findings provide structure–activity relationships and show how pathogen resistance can be overcome by natural scaffold diversity. The most promising derivative 861-2 was prepared by total synthesis, enabling further chemical optimization of this privileged scaffold.",
keywords = "cystobactamids, gyrase inhibitors, myxobacteria, natural products, total synthesis",
author = "Stephan H{\"u}ttel and Giambattista Testolin and Jennifer Herrmann and Therese Planke and Franziska Gille and Maria Moreno and Marc Stadler and Mark Br{\"o}nstrup and Andreas Kirschning and Rolf M{\"u}ller",
note = "Funding information: This project was funded by the German Center for Infection Research (DZIF) to HZI and LUH and the Fonds der Chemischen Industrie. We thank Silke Reinecke and Viktoria Schmitt for excellent technical assistance and Dr. Kirsten Harmrolfs for careful proofreading of the manuscript.",
year = "2017",
month = jul,
day = "20",
doi = "10.1002/anie.201705913",
language = "English",
volume = "56",
pages = "12760--12764",
journal = "Angewandte Chemie ",
issn = "1433-7851",
publisher = "John Wiley and Sons Ltd",
number = "41",

}

Download

TY - JOUR

T1 - Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens

AU - Hüttel, Stephan

AU - Testolin, Giambattista

AU - Herrmann, Jennifer

AU - Planke, Therese

AU - Gille, Franziska

AU - Moreno, Maria

AU - Stadler, Marc

AU - Brönstrup, Mark

AU - Kirschning, Andreas

AU - Müller, Rolf

N1 - Funding information: This project was funded by the German Center for Infection Research (DZIF) to HZI and LUH and the Fonds der Chemischen Industrie. We thank Silke Reinecke and Viktoria Schmitt for excellent technical assistance and Dr. Kirsten Harmrolfs for careful proofreading of the manuscript.

PY - 2017/7/20

Y1 - 2017/7/20

N2 - Antibiotic discovery and development is challenging as chemical scaffolds of synthetic origin often lack the required pharmaceutical properties, and the discovery of novel ones from natural sources is tedious. Herein, we report the discovery of new cystobactamids with a significantly improved antibacterial profile in a detailed screening of myxobacterial producer strains. Some of these new derivatives display antibacterial activities in the low-μg mL−1 range against Gram-negative pathogens, including clinical isolates of Klebsiella oxytoca, Pseudomonas aeruginosa, and fluoroquinolone-resistant Enterobacteriaceae, which were not observed for previously reported cystobactamids. Our findings provide structure–activity relationships and show how pathogen resistance can be overcome by natural scaffold diversity. The most promising derivative 861-2 was prepared by total synthesis, enabling further chemical optimization of this privileged scaffold.

AB - Antibiotic discovery and development is challenging as chemical scaffolds of synthetic origin often lack the required pharmaceutical properties, and the discovery of novel ones from natural sources is tedious. Herein, we report the discovery of new cystobactamids with a significantly improved antibacterial profile in a detailed screening of myxobacterial producer strains. Some of these new derivatives display antibacterial activities in the low-μg mL−1 range against Gram-negative pathogens, including clinical isolates of Klebsiella oxytoca, Pseudomonas aeruginosa, and fluoroquinolone-resistant Enterobacteriaceae, which were not observed for previously reported cystobactamids. Our findings provide structure–activity relationships and show how pathogen resistance can be overcome by natural scaffold diversity. The most promising derivative 861-2 was prepared by total synthesis, enabling further chemical optimization of this privileged scaffold.

KW - cystobactamids

KW - gyrase inhibitors

KW - myxobacteria

KW - natural products

KW - total synthesis

UR - http://www.scopus.com/inward/record.url?scp=85028530229&partnerID=8YFLogxK

U2 - 10.1002/anie.201705913

DO - 10.1002/anie.201705913

M3 - Article

C2 - 28730677

AN - SCOPUS:85028530229

VL - 56

SP - 12760

EP - 12764

JO - Angewandte Chemie

JF - Angewandte Chemie

SN - 1433-7851

IS - 41

ER -

Von denselben Autoren